



Docket No.: SAEG193.001APC

1646 Ives  
August 29, 2006

Page 1 of 1

Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Ueda et al.  
App. No : 10/549,555  
Filed : June 29, 2006  
For : THERAPEUTIC PRODUCT FOR  
TREATING HEMOPHILIA AND  
METHOD OF TREATING HEMOPHILIA  
USING THE SAME  
Examiner : Unknown  
Art Unit : 1646

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 29, 2006

(Date)

Eric Ives, Reg. No. 50,928

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:  
(X) Listing 5 references.  
(X) Enclosing 5 references.  
(X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Eric Ives  
Registration No. 50,928  
Agent of Record  
Customer No. 20,995  
(805) 547-5580

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Ueda et al.  
App. No : 10/549,555  
Filed : June 29, 2006  
For : THERAPEUTIC PRODUCT FOR  
TREATING HEMOPHILIA AND  
METHOD OF TREATING  
HEMOPHILIA USING THE SAME  
Examiner : Unknown  
Art Unit : 1646

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 5 references to be considered by the Examiner. Also enclosed are 5 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.


This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 6-29-2006

By: Eric Ives  
Eric Ives  
Registration No. 50,928  
Agent of Record  
Customer No. 20,995  
(805) 547-5580



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/549,555
Filing Date	June 29, 2006
First Named Inventor	Ueda, Masakazu
Art Unit	1646
Examiner	Unknown
Attorney Docket No.	SAEG193.001APC

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number <i>Number - Kind Code (if known)</i> Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document <i>Country Code-Number-Kind Code</i> Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	EP 1 262 555 A1	12-04-2002	Japan Science & Tech		
	2	WO 02/086091 A2	10-31-2002	UC Regents – California		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	3	GNATENKO, D. et al. (1999) "Human factor VIII can be packaged and functionally expressed in anadeno-associated virus background: applicability to haemophilia A gene therapy" British Journal of Haematology 104:27-36.	
	4	YAMADA, T. et al. (2001) "Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 +S) protein" Vaccine 19:3154-3163.	
	5	SUPPLEMENTARY EUROPEAN SEARCH REPORT from corresponding European patent application serial no. 04 72 1332.	

2871462  
082406

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.